Table 5.
Ongoing phase I or II trials in osteosarcoma (Assessed from www.ClinicalTrials.gov)
| ClinicalTrials.gov Identifier | Sponsors | Title | Status |
|---|---|---|---|
| NCT00102531 | Transave | Phase Ib/IIa non-randomised study of SLIT Cisplatin by inhalation in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung | Recruiting |
| NCT01002092 | Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd |
A randomized, controlled multicenter trial of Endostar combined with chemotherapy for treatment of osteosarcoma (phase II) | Recruiting |
| NCT00889057 | Italian Sarcoma Group | Phase II, open label, non-randomized study of second or third line treatment with Sorafenib (BAY 43-9006) in patients affected by relapsed high-grade osteosarcoma | Recruiting |
|
NCT00752206 NCT00923286 |
Sarcoma Alliance for Research through Collaboration (SARC) | A randomized, double-blinded, placebo-controlled, multi-institutional, phase II study of AZD0530, a selective Src kinase inhibitor, in patients with recurrent osteosarcoma localized to the lung | Recruiting |
| NCT01005043 | University of Heidelberg | Phase I/II therapy non-randomised trial to determine the safety and efficacy of heavy ion radiotherapy in patients with osteosarcoma | Not yet recruiting |
| NCT00902044 | Baylor College of Medicine | Administration of Her2 Chimeric antigen receptor expressing T Cells for subjects with advanced osteosarcoma (HEROS) (phase I) | Not yet recruiting |